August 7, 2024
Bespak is pleased to announce it has joined the International Pharmaceutical Aerosol Consortium (IPAC), reflecting its standing as a key player in the transition to low global warming potential (GWP) propellants.
IPAC was formed in response to the Montreal Protocol – a mandate designed to combat substances that deplete the ozone layer and address the contribution of inhalation products to climate change. The consortium engages in policy issues around the world and strives to ensure that global environmental policies impacting inhaled therapies are patient-centric and appropriately balance patient care with sustainability efforts and objectives.
Louise Righton, Head of Strategic Marketing, and Simon Gardner, Business Development Director, will be representing Bespak on the IPAC Board.
Additionally, as an existing member of IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation & Science) Bespak welcomes the appointment of Dr. Lei Mao, Director of Inhalation Sciences and Product Development at Bespak, as Vice Chair commencing July 2024. Ross Errington, Bespak’s Head of Drug Product Development, will also serve on the Board of IPAC-RS with immediate effect.
IPAC-RS is an international association dedicated to advancing the regulatory science of inhalation drug products. Representing the orally inhaled and nasal drug product (OINDP) industry for more than 20 years, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing research at conferences, technical journals, webinars, and through ongoing discussions with regulatory bodies.
Righton, Gardner, Mao and Errington will be working closely with IPAC and IPAC-RS to support industry-wide efforts to advance the development, regulatory approval and commercialisation of low GWP pressurised metered dose inhalers (pMDIs).
Having membership of both IPAC and IPAC-RS will enhance Bespak’s engagement in the inhalation community, as the company will contribute to the implementation of global environmental regulations and standards relating to OINDPs. It will also enable collaboration with other industry leaders – sharing knowledge more effectively to advance the research and development of new inhalation technologies.
Chris Hirst, CEO at Bespak, said: “We are delighted to have the opportunity to collaborate with the inhalation community as IPAC and IPAC-RS members. It’s inspiring to us all to see the pharmaceutical industry at the forefront of the change to climate-friendly propellants. At Bespak, collaborating with our partners to bring greener, low GWP propellants to a product used by so many is something we are proud to be a part of. We are looking forward to working together with our industry peers in these two global consortiums to achieve a smooth transition that prioritises the care of patients and respects our planet.”